Crinetics Pharmaceuticals, Inc.
CRNXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeCrinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and. The $8.88B market capitalization puts CRNX squarely in mid-cap range for its industry. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
Market Cap
$8.88B
Beta
0.23
P/E (TTM)
—
P/E (Fwd)
-20.61
EPS (TTM)
$-5.14
EPS (Fwd)
$-4.07
ROE
-39.2%
ROA
-24.7%
Cash
$1.29B
Total Debt
$47.9M
Free CF
-$242.1M
52W Change
169.6%
Annual Financials
Cash vs Debt
Crinetics Pharmaceuticals, Inc. holds $1.29B in cash against $47.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$242.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -39.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $4.7M to $7.7M.
The relatively low beta of 0.23 suggests CRNX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, CRNX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Crinetics Pharmaceuticals, Inc.'s trajectory.